Department of Gastroenterology and Hepatology, University Hospital and University of Duisburg-Essen, Essen, Germany.
Department of Internal Medicine 1, Goethe-University Hospital Frankfurt, Frankfurt, Germany.
Front Immunol. 2021 Jan 26;11:534731. doi: 10.3389/fimmu.2020.534731. eCollection 2020.
INTRODUCTION: Acute-on-chronic liver failure (ACLF) is characterized by high levels of systemic inflammation and parallel suppression of innate immunity, whereas little is known about adaptive immune immunity in ACLF. We therefore aimed to characterize the development of the adaptive immune system during the progression of liver cirrhosis to ACLF. Patients with compensated/stable decompensated liver cirrhosis, acute decompensation of liver cirrhosis, or ACLF were recruited from a prospective cohort study. Comprehensive immunophenotyping was performed using high dimensional flow cytometry. Replication of (TT) virus was quantified as a marker of immunosuppression. High frequencies of detectable TT virus were observed already in patients with compensated/stable decompensated liver cirrhosis compared to healthy controls (>50% vs. 19%), suggesting relatively early occurrence of immunosuppression in cirrhosis. In line, profoundly reduced numbers of distinct innate and adaptive immune cell populations were observed before ACLF development. These changes were accompanied by parallel upregulation of co-stimulatory (e.g. CD40L, OX40, CD69, GITR, TIM-1) and inhibitory immune checkpoints (e.g. PDPN, PROCR, 2B4, TIGIT) on CD4+ and CD8+ T cells, which again preceded the development of ACLF. On a functional basis, the capacity of CD4+ and CD8+ T cells to produce pro-inflammatory cytokines upon stimulation was strongly diminished in patients with acute decompensation of liver cirrhosis and ACLF. CONCLUSION: Impaired innate and-in particular-adaptive cellular immunity occurs relatively early in the pathogenesis of liver cirrhosis and precedes ACLF. This may contribute to the development of ACLF by increasing the risk of infections in patients with liver cirrhosis.
简介:慢加急性肝衰竭(ACLF)的特点是全身性炎症水平高,同时先天免疫受到抑制,而对于 ACLF 中的适应性免疫知之甚少。因此,我们旨在描述肝硬化进展为 ACLF 过程中适应性免疫系统的发展情况。从一项前瞻性队列研究中招募了代偿/稳定失代偿性肝硬化、急性肝失代偿和 ACLF 患者。使用高维流式细胞术进行全面免疫表型分析。作为免疫抑制的标志物,对(TT)病毒的复制进行定量。与健康对照组相比,代偿/稳定失代偿性肝硬化患者中已可检测到高频率的 TT 病毒(>50%比 19%),这表明免疫抑制在肝硬化中相对较早发生。同样,在 ACLF 发生之前,就已经观察到固有和适应性免疫细胞群的数量明显减少。这些变化伴随着共刺激(例如 CD40L、OX40、CD69、GITR、TIM-1)和抑制性免疫检查点(例如 PDPN、PROCR、2B4、TIGIT)在 CD4+和 CD8+T 细胞上的平行上调,这再次发生在 ACLF 发生之前。从功能基础上看,CD4+和 CD8+T 细胞在受到刺激时产生促炎细胞因子的能力在急性肝失代偿和 ACLF 患者中明显减弱。
结论:在肝硬化发病机制中,固有和特别是适应性细胞免疫受损相对较早发生,并先于 ACLF。这可能通过增加肝硬化患者感染的风险,导致 ACLF 的发生。
J Clin Transl Hepatol. 2024-10-28
Cancers (Basel). 2024-7-22
Int J Mol Sci. 2024-1-23
Liver Int. 2025-3
Gut. 2017-3
Nat Rev Drug Discov. 2016-3-29